Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Compact case
Case
-
Reference no. 9-506-062
Published by: Harvard Business Publishing
Originally published in: 2006
Version: 4 February 2009
Length: 4 pages
Data source: Published sources

Abstract

Abbott Labs has reached an impasse with the Brazilian government in negotiations over the pricing of a new anti-AIDS drug, Kaletra. The Brazilian government threatens compulsory licensing unless Abbott drastically reduces the price of Kaletra.
Location:
Other setting(s):
2005

About

Abstract

Abbott Labs has reached an impasse with the Brazilian government in negotiations over the pricing of a new anti-AIDS drug, Kaletra. The Brazilian government threatens compulsory licensing unless Abbott drastically reduces the price of Kaletra.

Settings

Location:
Other setting(s):
2005

Related